Economic Impact of Neutropenia and Febrile Neutropenia in Breast Cancer: Estimates from Two National Databases

Authors:

Abstract
Study Objective. To estimate the economic burden of neutropenia and febrile neutropenia in female breast cancer hospital admissions in the United States. Design. Retrospective database analysis. Patients. Female admissions with a breast cancer diagnosis. Measurements and Main Results. By reviewing two national databases (Healthcare Costs and Utilization Project, MarketScan), length of stay and charge or payment/admission were estimated from 1994–1996. Neutropenic and febrile neutropenic admissions were longer and incurred higher charges and payments than nonneutropenic and afebrile neutropenic admissions, respectively (pConclusion. There was a trend toward decreased charges for inpatient admissions with neutropenia in patients with breast cancer (1994–1996). Interventions that reduce the frequency of neutropenia and febrile neutropenia could reduce hospitalization costs of breast cancer admissions.

This publication has 24 references indexed in Scilit: